A detailed history of Boston Common Asset Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Boston Common Asset Management, LLC holds 50,266 shares of VRTX stock, worth $22.7 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares
50,266
Previous 37,258 34.91%
Holding current value
$22.7 Million
Previous $17.5 Million 33.86%
% of portfolio
0.61%
Previous 0.45%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 09, 2024

BUY
$460.0 - $505.78 $5.98 Million - $6.58 Million
13,008 Added 34.91%
50,266 $23.4 Million
Q2 2024

Jul 08, 2024

SELL
$392.81 - $485.53 $809,581 - $1 Million
-2,061 Reduced 5.24%
37,258 $17.5 Million
Q1 2024

Apr 11, 2024

SELL
$407.69 - $446.08 $6.54 Million - $7.15 Million
-16,038 Reduced 28.97%
39,319 $16.4 Million
Q4 2023

Jan 09, 2024

SELL
$343.0 - $410.68 $915,810 - $1.1 Million
-2,670 Reduced 4.6%
55,357 $22.5 Million
Q3 2023

Oct 11, 2023

SELL
$338.18 - $362.46 $409,197 - $438,576
-1,210 Reduced 2.04%
58,027 $20.2 Million
Q2 2023

Jul 24, 2023

SELL
$314.42 - $351.91 $4.87 Million - $5.45 Million
-15,499 Reduced 20.74%
59,237 $20.8 Million
Q1 2023

May 17, 2023

SELL
$283.23 - $323.1 $727,334 - $829,720
-2,568 Reduced 3.32%
74,736 $23.5 Million
Q4 2022

Jan 26, 2023

BUY
$285.76 - $321.48 $579,235 - $651,639
2,027 Added 2.69%
77,304 $22.3 Million
Q3 2022

Oct 20, 2022

BUY
$273.83 - $305.53 $5.56 Million - $6.2 Million
20,308 Added 36.94%
75,277 $21.8 Million
Q2 2022

Aug 10, 2022

BUY
$234.96 - $292.55 $5.42 Million - $6.75 Million
23,085 Added 72.4%
54,969 $15.5 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $186,878 - $220,258
844 Added 2.72%
31,884 $8.32 Million
Q4 2021

Jan 31, 2022

SELL
$177.01 - $223.45 $89,390 - $112,842
-505 Reduced 1.6%
31,040 $6.82 Million
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $30,654 - $34,305
-169 Reduced 0.53%
31,545 $5.72 Million
Q2 2021

Aug 19, 2021

BUY
$187.49 - $221.1 $1.43 Million - $1.69 Million
7,635 Added 31.71%
31,714 $6.39 Million
Q1 2021

May 14, 2021

BUY
$207.02 - $241.31 $4.98 Million - $5.81 Million
24,079 New
24,079 $5.17 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Boston Common Asset Management, LLC Portfolio

Follow Boston Common Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Common Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boston Common Asset Management, LLC with notifications on news.